Legal Representation
Attorney
Stephanie A. Gumm
USPTO Deadlines
Next Deadline
1956 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-11-19)
Due Date
November 19, 2030
Grace Period Ends
May 19, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
24 events| Date | Code | Type | Description |
|---|---|---|---|
| Nov 19, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Nov 19, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Sep 3, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Sep 3, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Aug 14, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Jul 29, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Jul 29, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED |
| Jul 29, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Jul 29, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jul 29, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Jul 23, 2024 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Mar 19, 2024 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY |
| Mar 19, 2024 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY |
| Mar 6, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Mar 6, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Mar 6, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Mar 6, 2024 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| Mar 6, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Feb 1, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Feb 1, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED |
| Feb 1, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jan 29, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
| May 31, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| May 5, 2023 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 038
Providing online educational forums in the field of disease advocacy for disease advocacy organizations and their stakeholders to share experiences, develop best practices, and promote sound policy solutions for patient-focused drug development
First Use Anywhere:
Jan 6, 2020
First Use in Commerce:
Jan 6, 2020
Classification
International Classes
038